Glenmark Pharma share price falls 2.1% in today's session; stock among top losers on Nifty Midcap 150

Shares of Glenmark Pharma declined by 2.1% to Rs 2,019.50 in Friday's session, making it one of the top losers on the Nifty Midcap 150. The stock's movement reflects a decrease from its previous close.

Financial Snapshot:

Here's a look at the key financial data for Glenmark Pharma:

Consolidated Quarterly Performance:

The revenue for Glenmark Pharma has fluctuated over the past five quarters, with a high of Rs 3,433.80 Crore in September 2024 and a recent value of Rs 3,256.21 Crore in March 2025. Net profit saw a significant recovery from a loss of Rs 1,214.27 Crore in March 2024 to a profit, although a modest Rs 4.38 Crore in March 2025. Similarly, the EPS has improved from -43.18 in March 2024 to 0.16 in March 2025.

Consolidated Yearly Performance:

The yearly revenue for Glenmark Pharma has shown growth, reaching Rs 13,321.74 Crore for the year-ending March 2025, compared to Rs 11,813.10 Crore in the year-ending March 2024. Net profit also recovered significantly to Rs 1,047.14 Crore in the year-ending March 2025, after a loss of Rs 1,830.85 Crore in the year-ending March 2024. The EPS also reflects this recovery, increasing to 37.11 in the year-ending March 2025 from -53.22 in the year-ending March 2024.

Consolidated Yearly Income Statement:

Consolidated Quarterly Income Statement:Consolidated Balance Sheet:Consolidated Cash Flow:Key Financial Ratios:
Glenmark Pharma announced several corporate actions, including board meetings for financial results and dividend declarations. The company's board is scheduled to meet on August 14, 2025, to consider and approve the unaudited financial results for the first quarter ended June 30, 2025. Additionally, the trading window was closed from June 30, 2025, to August 16, 2025, for the approval of these results. The company has also consistently declared final dividends of Rs 2.50 per share over the past five years. A bonus issue was announced on January 6, 2005, with a bonus ratio of 1:1 and an ex-bonus date of March 4, 2005. Furthermore, the stock underwent splits, including one on September 10, 2007, with the old face value of Rs 2 being split into a new face value of Rs 1, and another on October 23, 2003, with the old face value of Rs 10 being split into a new face value of Rs 2.

Moneycontrol's sentiment analysis as of August 1, 2025, suggests a bullish outlook for the stock.

With the stock's last traded price at Rs 2,019.50, Glenmark Pharma is currently trading among the top losers on the Nifty Midcap 150.